Re: The antimalarial artemisinin synergizes with antibiotics

August 10, 2006

Artemisinin may synergize with your brain cells as well. I can send

the full article on this to anyone interested. (You folks are so

adamantly opposed to the MP, you should be as adamantly opposed to

artimisinin.)

Toxicology Letters

Article in Press, Corrected Proof - Note to users

This Document

SummaryPlus

Full Text + Links

PDF (200 K)

Actions

Cited By

Save as Citation Alert

E-mail Article

Export Citation

doi:10.1016/j.toxlet.2006.06.001

Mini review

Are currently deployed artemisinins neurotoxic?

Tooveya, b, ,

aRoyal Free and University College Medical School, London, UK

bTravel Clinic, Cape Town, South Africa

Received 28 April 2006; revised 31 May 2006; accepted 1 June 2006.

Available online 7 June 2006.

Abstract

In vitro, animal, and human clinical studies suggest currently

deployed artemisinins possess neurotoxic potential. A specific and

consistent pattern of brainstem injuries that includes auditory

processing centers has been reported from all laboratory animals

studied. Hearing loss, ataxia, and tremor are reported from humans.

Neurotoxicity appears mediated in part through artemisinin induced

oxidative stress in exposed brainstems. In vitro studies suggest that

artemisinin neurotoxicity does not manifest immediately upon

exposure, but that once commenced it is inevitable and irreversible;

extrapolation from in vitro data suggests that 14 days may possibly

be required for full development, casting doubt upon some animal

safety studies and human necropsy studies. Uncertainty remains over

the neurotoxicity of currently deployed artemisinins, and their

safety profile should be reviewed, especially in pediatric use. The

development of non-neurotoxic artemisinins is possible and should be

encouraged.

Keywords: Artemisinin; Artemether; Artesunate; Dihydroartemisinin;

Neurotoxicity; Ototoxicity; Malaria; Cancer

>

> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search & DB=pubmed

>

> Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

>

> The antimalarial artemisinin synergizes with antibiotics to

protect

> against lethal live Escherichia coli challenge by decreasing

> proinflammatory cytokine release.

>

> * Wang J, Zhou H, Zheng J, etc.

>

> Department of Pharmacology, College of Medicine, The Third

Military

> Medical University, Gaotanyan Street 30, Shapingba District,

Chongqing

> 400038, People's Republic of China.

>

> In the present study artemisinin (ART) was found to have potent

> anti-inflammatory effects in animal models of sepsis induced by

> CpG-containing oligodeoxy-nucleotides (CpG ODN), lipopolysaccharide

> (LPS), heat-killed Escherichia coli 35218 or live E. coli.

Furthermore,

> we found that ART protected mice from a lethal challenge by CpG

ODN,

> LPS, or heat-killed E. coli in a dose-dependent manner and that the

> protection was related to a reduction in serum tumor necrosis

factor

> alpha (TNF-alpha). More significantly, the administration of ART

> together with ampicillin or unasyn (a complex of ampicillin and

> sulbactam) decreased mortality from 100 to 66.7% or 33.3%,

respectively,

> in mice subjected to a lethal live E. coli challenge. Together with

the

> observation that ART alone does not inhibit bacterial growth, this

> result suggests that ART protection is achieved as a result of its

> anti-inflammatory activity rather than an antimicrobial effect. In

> RAW264.7 cells, pretreatment with ART potently inhibited TNF-alpha

and

> interleukin-6 release induced by CpG ODN, LPS, or heat-killed E.

coli in

> a dose- and time-dependent manner. Experiments utilizing affinity

sensor

> technology revealed no direct binding of ART with CpG ODN or LPS.

Flow

> cytometry further showed that ART did not alter binding of CpG ODN

to

> cell surfaces or the internalization of CpG ODN. In addition,

> upregulated levels of TLR9 and TLR4 mRNA were not attenuated by ART

> treatment. ART treatment did, however, block the NF-kappaB

activation

> induced by CpG ODN, LPS, or heat-killed E. coli. These findings

provide

> compelling evidence that ART may be an important potential drug for

> sepsis treatment.

>

> PMID: 16801421 [PubMed - in process]

>

August 10, 2006

a

One of the obvious differences is that there's no one making $$ off

$45.00 DVDs on Artesiminin.

(Aw- come on- it's not all bad-. it's just the marketing stragety

muddies what ever pearls are there.)

Barb

--- In infections , " pjeanneus " <pj7@...>

wrote:

>

(You folks are so

> adamantly opposed to the MP, you should be as adamantly opposed to

> artimisinin.)

>

August 10, 2006

I assume this is for the DRUG and not the herb.

People do not make the distinction and it's hard to tell what they're

talking about.

The DRUG for malaria is a 5 day regime.

As far as I know no one takes it longer than that.

The herb though is another story-

and I agree- it has never seemed to me like something to take long

term.

Barb

>

> Artemisinin may synergize with your brain cells as well. I can send

> the full article on this to anyone interested. (You folks are so

> adamantly opposed to the MP, you should be as adamantly opposed to

> artimisinin.)

>

> Toxicology Letters

> Article in Press, Corrected Proof - Note to users

>

> This Document

>

> SummaryPlus

> Full Text + Links

> PDF (200 K)

>

> Actions

>

> Cited By

>

> Save as Citation Alert

>

> E-mail Article

>

> Export Citation

>

> doi:10.1016/j.toxlet.2006.06.001

> Mini review

> Are currently deployed artemisinins neurotoxic?

>

> Tooveya, b, ,

>

> aRoyal Free and University College Medical School, London, UK

> bTravel Clinic, Cape Town, South Africa

>

> Received 28 April 2006; revised 31 May 2006; accepted 1 June

2006.

> Available online 7 June 2006.

>

> Abstract

> In vitro, animal, and human clinical studies suggest currently

> deployed artemisinins possess neurotoxic potential. A specific and

> consistent pattern of brainstem injuries that includes auditory

> processing centers has been reported from all laboratory animals

> studied. Hearing loss, ataxia, and tremor are reported from humans.

> Neurotoxicity appears mediated in part through artemisinin induced

> oxidative stress in exposed brainstems. In vitro studies suggest

that

> artemisinin neurotoxicity does not manifest immediately upon

> exposure, but that once commenced it is inevitable and

irreversible;

> extrapolation from in vitro data suggests that 14 days may possibly

> be required for full development, casting doubt upon some animal

> safety studies and human necropsy studies. Uncertainty remains over

> the neurotoxicity of currently deployed artemisinins, and their

> safety profile should be reviewed, especially in pediatric use. The

> development of non-neurotoxic artemisinins is possible and should

be

> encouraged.

>

> Keywords: Artemisinin; Artemether; Artesunate; Dihydroartemisinin;

> Neurotoxicity; Ototoxicity; Malaria; Cancer

>

> >

> > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search & DB=pubmed

> >

> > Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

> >

> > The antimalarial artemisinin synergizes with antibiotics to

> protect

> > against lethal live Escherichia coli challenge by decreasing

> > proinflammatory cytokine release.

> >

> > * Wang J, Zhou H, Zheng J, etc.

> >

> > Department of Pharmacology, College of Medicine, The Third

> Military

> > Medical University, Gaotanyan Street 30, Shapingba District,

> Chongqing

> > 400038, People's Republic of China.

> >

> > In the present study artemisinin (ART) was found to have

potent

> > anti-inflammatory effects in animal models of sepsis induced by

> > CpG-containing oligodeoxy-nucleotides (CpG ODN),

lipopolysaccharide

> > (LPS), heat-killed Escherichia coli 35218 or live E. coli.

> Furthermore,

> > we found that ART protected mice from a lethal challenge by CpG

> ODN,

> > LPS, or heat-killed E. coli in a dose-dependent manner and that

the

> > protection was related to a reduction in serum tumor necrosis

> factor

> > alpha (TNF-alpha). More significantly, the administration of ART

> > together with ampicillin or unasyn (a complex of ampicillin and

> > sulbactam) decreased mortality from 100 to 66.7% or 33.3%,

> respectively,

> > in mice subjected to a lethal live E. coli challenge. Together

with

> the

> > observation that ART alone does not inhibit bacterial growth,

this

> > result suggests that ART protection is achieved as a result of

its

> > anti-inflammatory activity rather than an antimicrobial effect.

In

> > RAW264.7 cells, pretreatment with ART potently inhibited TNF-

alpha

> and

> > interleukin-6 release induced by CpG ODN, LPS, or heat-killed E.

> coli in

> > a dose- and time-dependent manner. Experiments utilizing affinity

> sensor

> > technology revealed no direct binding of ART with CpG ODN or LPS.

> Flow

> > cytometry further showed that ART did not alter binding of CpG

ODN

> to

> > cell surfaces or the internalization of CpG ODN. In addition,

> > upregulated levels of TLR9 and TLR4 mRNA were not attenuated by

ART

> > treatment. ART treatment did, however, block the NF-kappaB

> activation

> > induced by CpG ODN, LPS, or heat-killed E. coli. These findings

> provide

> > compelling evidence that ART may be an important potential drug

for

> > sepsis treatment.

> >

> > PMID: 16801421 [PubMed - in process]

> >

>

August 10, 2006

****You folks are so

> adamantly opposed to the MP,****says a?

a,my butt hasn't been the same since doing that protocol.Also I

must admit it really calmed the inflkammation in the beginning, but

it was all lost not long after the early part for me.Mind you I tried

on several other occasions to see if the inflammation was tamed yet

nada. Also why would you want to order someones dvd's when you've

already read the book. (green eggs and benicar)

I think there's not too many healthy puppies over at his site. Also

that aussie lady should be just about jumping thru hoops about now,

since she did everything to the letter, especially the suffering

bit.. What are your impressions of the long term group? Just beware

the brainwashed IMO ... these are the people that are so braindead

everything is better than nothing, I suppose. Your take on this whole

thing would be interesting PAula

>

> Artemisinin may synergize with your brain cells as well. I can send

> the full article on this to anyone interested. (You folks are so

> adamantly opposed to the MP, you should be as adamantly opposed to

> artimisinin.)

>

> Toxicology Letters

> Article in Press, Corrected Proof - Note to users

>

> This Document

>

> SummaryPlus

> Full Text + Links

> PDF (200 K)

>

> Actions

>

> Cited By

>

> Save as Citation Alert

>

> E-mail Article

>

> Export Citation

>

> doi:10.1016/j.toxlet.2006.06.001

> Mini review

> Are currently deployed artemisinins neurotoxic?

>

> Tooveya, b, ,

>

> aRoyal Free and University College Medical School, London, UK

> bTravel Clinic, Cape Town, South Africa

>

> Received 28 April 2006; revised 31 May 2006; accepted 1 June

2006.

> Available online 7 June 2006.

>

> Abstract

> In vitro, animal, and human clinical studies suggest currently

> deployed artemisinins possess neurotoxic potential. A specific and

> consistent pattern of brainstem injuries that includes auditory

> processing centers has been reported from all laboratory animals

> studied. Hearing loss, ataxia, and tremor are reported from humans.

> Neurotoxicity appears mediated in part through artemisinin induced

> oxidative stress in exposed brainstems. In vitro studies suggest

that

> artemisinin neurotoxicity does not manifest immediately upon

> exposure, but that once commenced it is inevitable and

irreversible;

> extrapolation from in vitro data suggests that 14 days may possibly

> be required for full development, casting doubt upon some animal

> safety studies and human necropsy studies. Uncertainty remains over

> the neurotoxicity of currently deployed artemisinins, and their

> safety profile should be reviewed, especially in pediatric use. The

> development of non-neurotoxic artemisinins is possible and should

be

> encouraged.

>

> Keywords: Artemisinin; Artemether; Artesunate; Dihydroartemisinin;

> Neurotoxicity; Ototoxicity; Malaria; Cancer

>

> >

> > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search & DB=pubmed

> >

> > Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

> >

> > The antimalarial artemisinin synergizes with antibiotics to

> protect

> > against lethal live Escherichia coli challenge by decreasing

> > proinflammatory cytokine release.

> >

> > * Wang J, Zhou H, Zheng J, etc.

> >

> > Department of Pharmacology, College of Medicine, The Third

> Military

> > Medical University, Gaotanyan Street 30, Shapingba District,

> Chongqing

> > 400038, People's Republic of China.

> >

> > In the present study artemisinin (ART) was found to have

potent

> > anti-inflammatory effects in animal models of sepsis induced by

> > CpG-containing oligodeoxy-nucleotides (CpG ODN),

lipopolysaccharide

> > (LPS), heat-killed Escherichia coli 35218 or live E. coli.

> Furthermore,

> > we found that ART protected mice from a lethal challenge by CpG

> ODN,

> > LPS, or heat-killed E. coli in a dose-dependent manner and that

the

> > protection was related to a reduction in serum tumor necrosis

> factor

> > alpha (TNF-alpha). More significantly, the administration of ART

> > together with ampicillin or unasyn (a complex of ampicillin and

> > sulbactam) decreased mortality from 100 to 66.7% or 33.3%,

> respectively,

> > in mice subjected to a lethal live E. coli challenge. Together

with

> the

> > observation that ART alone does not inhibit bacterial growth,

this

> > result suggests that ART protection is achieved as a result of

its

> > anti-inflammatory activity rather than an antimicrobial effect.

In

> > RAW264.7 cells, pretreatment with ART potently inhibited TNF-

alpha

> and

> > interleukin-6 release induced by CpG ODN, LPS, or heat-killed E.

> coli in

> > a dose- and time-dependent manner. Experiments utilizing affinity

> sensor

> > technology revealed no direct binding of ART with CpG ODN or LPS.

> Flow

> > cytometry further showed that ART did not alter binding of CpG

ODN

> to

> > cell surfaces or the internalization of CpG ODN. In addition,

> > upregulated levels of TLR9 and TLR4 mRNA were not attenuated by

ART

> > treatment. ART treatment did, however, block the NF-kappaB

> activation

> > induced by CpG ODN, LPS, or heat-killed E. coli. These findings

> provide

> > compelling evidence that ART may be an important potential drug

for

> > sepsis treatment.

> >

> > PMID: 16801421 [PubMed - in process]

> >

>

August 10, 2006

What is the name of the drug for malaria? I assumed if the article

said " artemisinin " it was talking about the herbal treatment.

a Carnes

>

> I assume this is for the DRUG and not the herb.

> People do not make the distinction and it's hard to tell what

they're

> talking about.

>

> The DRUG for malaria is a 5 day regime.

> As far as I know no one takes it longer than that.

>

> The herb though is another story-

> and I agree- it has never seemed to me like something to take long

> term.

>

> Barb

>

> >

> > Artemisinin may synergize with your brain cells as well. I can

send

> > the full article on this to anyone interested. (You folks are so

> > adamantly opposed to the MP, you should be as adamantly opposed

to

> > artimisinin.)

> >

> > Toxicology Letters

> > Article in Press, Corrected Proof - Note to users

> >

> > This Document

> >

> > SummaryPlus

> > Full Text + Links

> > PDF (200 K)

> >

> > Actions

> >

> > Cited By

> >

> > Save as Citation Alert

> >

> > E-mail Article

> >

> > Export Citation

> >

> > doi:10.1016/j.toxlet.2006.06.001

> > Mini review

> > Are currently deployed artemisinins neurotoxic?

> >

> > Tooveya, b, ,

> >

> > aRoyal Free and University College Medical School, London, UK

> > bTravel Clinic, Cape Town, South Africa

> >

> > Received 28 April 2006; revised 31 May 2006; accepted 1 June

> 2006.

> > Available online 7 June 2006.

> >

> > Abstract

> > In vitro, animal, and human clinical studies suggest currently

> > deployed artemisinins possess neurotoxic potential. A specific

and

> > consistent pattern of brainstem injuries that includes auditory

> > processing centers has been reported from all laboratory animals

> > studied. Hearing loss, ataxia, and tremor are reported from

humans.

> > Neurotoxicity appears mediated in part through artemisinin

induced

> > oxidative stress in exposed brainstems. In vitro studies suggest

> that

> > artemisinin neurotoxicity does not manifest immediately upon

> > exposure, but that once commenced it is inevitable and

> irreversible;

> > extrapolation from in vitro data suggests that 14 days may

possibly

> > be required for full development, casting doubt upon some animal

> > safety studies and human necropsy studies. Uncertainty remains

over

> > the neurotoxicity of currently deployed artemisinins, and their

> > safety profile should be reviewed, especially in pediatric use.

The

> > development of non-neurotoxic artemisinins is possible and should

> be

> > encouraged.

> >

> > Keywords: Artemisinin; Artemether; Artesunate;

Dihydroartemisinin;

> > Neurotoxicity; Ototoxicity; Malaria; Cancer

> >

> > >

> > > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

CMD=search & DB=pubmed

> > >

> > > Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

> > >

> > > The antimalarial artemisinin synergizes with antibiotics to

> > protect

> > > against lethal live Escherichia coli challenge by decreasing

> > > proinflammatory cytokine release.

> > >

> > > * Wang J, Zhou H, Zheng J, etc.

> > >

> > > Department of Pharmacology, College of Medicine, The Third

> > Military

> > > Medical University, Gaotanyan Street 30, Shapingba District,

> > Chongqing

> > > 400038, People's Republic of China.

> > >

> > > In the present study artemisinin (ART) was found to have

> potent

> > > anti-inflammatory effects in animal models of sepsis induced by

> > > CpG-containing oligodeoxy-nucleotides (CpG ODN),

> lipopolysaccharide

> > > (LPS), heat-killed Escherichia coli 35218 or live E. coli.

> > Furthermore,

> > > we found that ART protected mice from a lethal challenge by CpG

> > ODN,

> > > LPS, or heat-killed E. coli in a dose-dependent manner and that

> the

> > > protection was related to a reduction in serum tumor necrosis

> > factor

> > > alpha (TNF-alpha). More significantly, the administration of

ART

> > > together with ampicillin or unasyn (a complex of ampicillin and

> > > sulbactam) decreased mortality from 100 to 66.7% or 33.3%,

> > respectively,

> > > in mice subjected to a lethal live E. coli challenge. Together

> with

> > the

> > > observation that ART alone does not inhibit bacterial growth,

> this

> > > result suggests that ART protection is achieved as a result of

> its

> > > anti-inflammatory activity rather than an antimicrobial effect.

> In

> > > RAW264.7 cells, pretreatment with ART potently inhibited TNF-

> alpha

> > and

> > > interleukin-6 release induced by CpG ODN, LPS, or heat-killed

E.

> > coli in

> > > a dose- and time-dependent manner. Experiments utilizing

affinity

> > sensor

> > > technology revealed no direct binding of ART with CpG ODN or

LPS.

> > Flow

> > > cytometry further showed that ART did not alter binding of CpG

> ODN

> > to

> > > cell surfaces or the internalization of CpG ODN. In addition,

> > > upregulated levels of TLR9 and TLR4 mRNA were not attenuated by

> ART

> > > treatment. ART treatment did, however, block the NF-kappaB

> > activation

> > > induced by CpG ODN, LPS, or heat-killed E. coli. These findings

> > provide

> > > compelling evidence that ART may be an important potential drug

> for

> > > sepsis treatment.

> > >

> > > PMID: 16801421 [PubMed - in process]

> > >

> >

>

August 10, 2006

Tony, my take is very similar to yours. I also felt the Benicar

helped at first. But after about a year I was much worse with severe

muscle weakness. I think the Benicar may have been damaging my

muscles. I also think that my immune system after years of

antibitoics to treat the mycoplasma and borrelia was already pretty

normal, so lowering D levels was ABNORMAL for me and made me sicker.

I also see several there who are still unbelievably sick. I think

they are kidding themselves. On the other hand I do know patients who

are doing okay. I also respect a couple of the doctors I know

personally who have many patients on the protocol.

But the difference between them and the stuff being promoted on the

website is this. The good doctors recognize that patients do not need

Benicar and D avoidance for a long time. They may need it for a few

months, but that is all. I remain convinced that the selection of

antibiotics is appropriate. Those who seem to be recovering are

probably getting well because they finally got on minocycline,

Zithromax and (Septrim.) That's my story and I'm stickin' to it.

I must add that I am finding Recuperation is doing wonders for me -

who knows.

a

>

> ****You folks are so

> > adamantly opposed to the MP,****says a?

>

> a,my butt hasn't been the same since doing that protocol.Also I

> must admit it really calmed the inflkammation in the beginning, but

> it was all lost not long after the early part for me.Mind you I

tried

> on several other occasions to see if the inflammation was tamed yet

> nada. Also why would you want to order someones dvd's when you've

> already read the book. (green eggs and benicar)

> I think there's not too many healthy puppies over at his site. Also

> that aussie lady should be just about jumping thru hoops about now,

> since she did everything to the letter, especially the suffering

> bit.. What are your impressions of the long term group? Just beware

> the brainwashed IMO ... these are the people that are so braindead

> everything is better than nothing, I suppose. Your take on this

whole

> thing would be interesting PAula

>

> >

> > Artemisinin may synergize with your brain cells as well. I can

send

> > the full article on this to anyone interested. (You folks are so

> > adamantly opposed to the MP, you should be as adamantly opposed

to

> > artimisinin.)

> >

> > Toxicology Letters

> > Article in Press, Corrected Proof - Note to users

> >

> > This Document

> >

> > SummaryPlus

> > Full Text + Links

> > PDF (200 K)

> >

> > Actions

> >

> > Cited By

> >

> > Save as Citation Alert

> >

> > E-mail Article

> >

> > Export Citation

> >

> > doi:10.1016/j.toxlet.2006.06.001

> > Mini review

> > Are currently deployed artemisinins neurotoxic?

> >

> > Tooveya, b, ,

> >

> > aRoyal Free and University College Medical School, London, UK

> > bTravel Clinic, Cape Town, South Africa

> >

> > Received 28 April 2006; revised 31 May 2006; accepted 1 June

> 2006.

> > Available online 7 June 2006.

> >

> > Abstract

> > In vitro, animal, and human clinical studies suggest currently

> > deployed artemisinins possess neurotoxic potential. A specific

and

> > consistent pattern of brainstem injuries that includes auditory

> > processing centers has been reported from all laboratory animals

> > studied. Hearing loss, ataxia, and tremor are reported from

humans.

> > Neurotoxicity appears mediated in part through artemisinin

induced

> > oxidative stress in exposed brainstems. In vitro studies suggest

> that

> > artemisinin neurotoxicity does not manifest immediately upon

> > exposure, but that once commenced it is inevitable and

> irreversible;

> > extrapolation from in vitro data suggests that 14 days may

possibly

> > be required for full development, casting doubt upon some animal

> > safety studies and human necropsy studies. Uncertainty remains

over

> > the neurotoxicity of currently deployed artemisinins, and their

> > safety profile should be reviewed, especially in pediatric use.

The

> > development of non-neurotoxic artemisinins is possible and should

> be

> > encouraged.

> >

> > Keywords: Artemisinin; Artemether; Artesunate;

Dihydroartemisinin;

> > Neurotoxicity; Ototoxicity; Malaria; Cancer

> >

> > >

> > > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

CMD=search & DB=pubmed

> > >

> > > Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

> > >

> > > The antimalarial artemisinin synergizes with antibiotics to

> > protect

> > > against lethal live Escherichia coli challenge by decreasing

> > > proinflammatory cytokine release.

> > >

> > > * Wang J, Zhou H, Zheng J, etc.

> > >

> > > Department of Pharmacology, College of Medicine, The Third

> > Military

> > > Medical University, Gaotanyan Street 30, Shapingba District,

> > Chongqing

> > > 400038, People's Republic of China.

> > >

> > > In the present study artemisinin (ART) was found to have

> potent

> > > anti-inflammatory effects in animal models of sepsis induced by

> > > CpG-containing oligodeoxy-nucleotides (CpG ODN),

> lipopolysaccharide

> > > (LPS), heat-killed Escherichia coli 35218 or live E. coli.

> > Furthermore,

> > > we found that ART protected mice from a lethal challenge by CpG

> > ODN,

> > > LPS, or heat-killed E. coli in a dose-dependent manner and that

> the

> > > protection was related to a reduction in serum tumor necrosis

> > factor

> > > alpha (TNF-alpha). More significantly, the administration of

ART

> > > together with ampicillin or unasyn (a complex of ampicillin and

> > > sulbactam) decreased mortality from 100 to 66.7% or 33.3%,

> > respectively,

> > > in mice subjected to a lethal live E. coli challenge. Together

> with

> > the

> > > observation that ART alone does not inhibit bacterial growth,

> this

> > > result suggests that ART protection is achieved as a result of

> its

> > > anti-inflammatory activity rather than an antimicrobial effect.

> In

> > > RAW264.7 cells, pretreatment with ART potently inhibited TNF-

> alpha

> > and

> > > interleukin-6 release induced by CpG ODN, LPS, or heat-killed

E.

> > coli in

> > > a dose- and time-dependent manner. Experiments utilizing

affinity

> > sensor

> > > technology revealed no direct binding of ART with CpG ODN or

LPS.

> > Flow

> > > cytometry further showed that ART did not alter binding of CpG

> ODN

> > to

> > > cell surfaces or the internalization of CpG ODN. In addition,

> > > upregulated levels of TLR9 and TLR4 mRNA were not attenuated by

> ART

> > > treatment. ART treatment did, however, block the NF-kappaB

> > activation

> > > induced by CpG ODN, LPS, or heat-killed E. coli. These findings

> > provide

> > > compelling evidence that ART may be an important potential drug

> for

> > > sepsis treatment.

> > >

> > > PMID: 16801421 [PubMed - in process]

> > >

> >

>

August 11, 2006

b- artemether:

Riamet, Coartem are the 2 drugs alreasy mixed with an abx.

Barb

> > >

> > > Artemisinin may synergize with your brain cells as well. I can

> send

> > > the full article on this to anyone interested. (You folks are

so

> > > adamantly opposed to the MP, you should be as adamantly opposed

> to

> > > artimisinin.)

> > >

> > > Toxicology Letters

> > > Article in Press, Corrected Proof - Note to users

> > >

> > > This Document

> > >

> > > SummaryPlus

> > > Full Text + Links

> > > PDF (200 K)

> > >

> > > Actions

> > >

> > > Cited By

> > >

> > > Save as Citation Alert

> > >

> > > E-mail Article

> > >

> > > Export Citation

> > >

> > > doi:10.1016/j.toxlet.2006.06.001

> > > Mini review

> > > Are currently deployed artemisinins neurotoxic?

> > >

> > > Tooveya, b, ,

> > >

> > > aRoyal Free and University College Medical School, London, UK

> > > bTravel Clinic, Cape Town, South Africa

> > >

> > > Received 28 April 2006; revised 31 May 2006; accepted 1 June

> > 2006.

> > > Available online 7 June 2006.

> > >

> > > Abstract

> > > In vitro, animal, and human clinical studies suggest currently

> > > deployed artemisinins possess neurotoxic potential. A specific

> and

> > > consistent pattern of brainstem injuries that includes auditory

> > > processing centers has been reported from all laboratory

animals

> > > studied. Hearing loss, ataxia, and tremor are reported from

> humans.

> > > Neurotoxicity appears mediated in part through artemisinin

> induced

> > > oxidative stress in exposed brainstems. In vitro studies

suggest

> > that

> > > artemisinin neurotoxicity does not manifest immediately upon

> > > exposure, but that once commenced it is inevitable and

> > irreversible;

> > > extrapolation from in vitro data suggests that 14 days may

> possibly

> > > be required for full development, casting doubt upon some

animal

> > > safety studies and human necropsy studies. Uncertainty remains

> over

> > > the neurotoxicity of currently deployed artemisinins, and their

> > > safety profile should be reviewed, especially in pediatric use.

> The

> > > development of non-neurotoxic artemisinins is possible and

should

> > be

> > > encouraged.

> > >

> > > Keywords: Artemisinin; Artemether; Artesunate;

> Dihydroartemisinin;

> > > Neurotoxicity; Ototoxicity; Malaria; Cancer

> > >

> > > >

> > > > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

> CMD=search & DB=pubmed

> > > >

> > > > Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

> > > >

> > > > The antimalarial artemisinin synergizes with antibiotics

to

> > > protect

> > > > against lethal live Escherichia coli challenge by decreasing

> > > > proinflammatory cytokine release.

> > > >

> > > > * Wang J, Zhou H, Zheng J, etc.

> > > >

> > > > Department of Pharmacology, College of Medicine, The

Third

> > > Military

> > > > Medical University, Gaotanyan Street 30, Shapingba District,

> > > Chongqing

> > > > 400038, People's Republic of China.

> > > >

> > > > In the present study artemisinin (ART) was found to have

> > potent

> > > > anti-inflammatory effects in animal models of sepsis induced

by

> > > > CpG-containing oligodeoxy-nucleotides (CpG ODN),

> > lipopolysaccharide

> > > > (LPS), heat-killed Escherichia coli 35218 or live E. coli.

> > > Furthermore,

> > > > we found that ART protected mice from a lethal challenge by

CpG

> > > ODN,

> > > > LPS, or heat-killed E. coli in a dose-dependent manner and

that

> > the

> > > > protection was related to a reduction in serum tumor necrosis

> > > factor

> > > > alpha (TNF-alpha). More significantly, the administration of

> ART

> > > > together with ampicillin or unasyn (a complex of ampicillin

and

> > > > sulbactam) decreased mortality from 100 to 66.7% or 33.3%,

> > > respectively,

> > > > in mice subjected to a lethal live E. coli challenge.

Together

> > with

> > > the

> > > > observation that ART alone does not inhibit bacterial growth,

> > this

> > > > result suggests that ART protection is achieved as a result

of

> > its

> > > > anti-inflammatory activity rather than an antimicrobial

effect.

> > In

> > > > RAW264.7 cells, pretreatment with ART potently inhibited TNF-

> > alpha

> > > and

> > > > interleukin-6 release induced by CpG ODN, LPS, or heat-killed

> E.

> > > coli in

> > > > a dose- and time-dependent manner. Experiments utilizing

> affinity

> > > sensor

> > > > technology revealed no direct binding of ART with CpG ODN or

> LPS.

> > > Flow

> > > > cytometry further showed that ART did not alter binding of

CpG

> > ODN

> > > to

> > > > cell surfaces or the internalization of CpG ODN. In addition,

> > > > upregulated levels of TLR9 and TLR4 mRNA were not attenuated

by

> > ART

> > > > treatment. ART treatment did, however, block the NF-kappaB

> > > activation

> > > > induced by CpG ODN, LPS, or heat-killed E. coli. These

findings

> > > provide

> > > > compelling evidence that ART may be an important potential

drug

> > for

> > > > sepsis treatment.

> > > >

> > > > PMID: 16801421 [PubMed - in process]

> > > >

> > >

> >

>

August 11, 2006

a

You have to be carefull not to hang your hat highly on a drug that's

worked well for yourself as a guide to what's good and bad(zithro). I

have seen many samples of bacteria that respond wildly, differently

to many agents and trevoars drug choices leave a lot to be

desired...especvially the low dose aspect that he stole straight out

of brown's arthritic site.I actually see first hand how using a drug

like minocycline grows bacteria in the low level presence of the

drug. I actually saw a great documentary on fake drugs and there

impact on the nigerian health system..This is a quote fromn the

female minister, a doctor/pharmacologist explaining that tyhe low

levels of chloroquine in the fake drugs are worse than anything she

has encountered, because now all the countries malaria treatments

see's the parasite use the chloroquine as food to grow.

I also see aspects of this in the false herxheimer experiment

practised on unwitting human beings over at the umentionable site-

with the umentionable latest release DVD's ..not to mention the

aussie chick from queensland and the meg ryan nursy answering the

guru's calling.

> > >

> > > Artemisinin may synergize with your brain cells as well. I can

> send

> > > the full article on this to anyone interested. (You folks are

so

> > > adamantly opposed to the MP, you should be as adamantly opposed

> to

> > > artimisinin.)

> > >

> > > Toxicology Letters

> > > Article in Press, Corrected Proof - Note to users

> > >

> > > This Document

> > >

> > > SummaryPlus

> > > Full Text + Links

> > > PDF (200 K)

> > >

> > > Actions

> > >

> > > Cited By

> > >

> > > Save as Citation Alert

> > >

> > > E-mail Article

> > >

> > > Export Citation

> > >

> > > doi:10.1016/j.toxlet.2006.06.001

> > > Mini review

> > > Are currently deployed artemisinins neurotoxic?

> > >

> > > Tooveya, b, ,

> > >

> > > aRoyal Free and University College Medical School, London, UK

> > > bTravel Clinic, Cape Town, South Africa

> > >

> > > Received 28 April 2006; revised 31 May 2006; accepted 1 June

> > 2006.

> > > Available online 7 June 2006.

> > >

> > > Abstract

> > > In vitro, animal, and human clinical studies suggest currently

> > > deployed artemisinins possess neurotoxic potential. A specific

> and

> > > consistent pattern of brainstem injuries that includes auditory

> > > processing centers has been reported from all laboratory

animals

> > > studied. Hearing loss, ataxia, and tremor are reported from

> humans.

> > > Neurotoxicity appears mediated in part through artemisinin

> induced

> > > oxidative stress in exposed brainstems. In vitro studies

suggest

> > that

> > > artemisinin neurotoxicity does not manifest immediately upon

> > > exposure, but that once commenced it is inevitable and

> > irreversible;

> > > extrapolation from in vitro data suggests that 14 days may

> possibly

> > > be required for full development, casting doubt upon some

animal

> > > safety studies and human necropsy studies. Uncertainty remains

> over

> > > the neurotoxicity of currently deployed artemisinins, and their

> > > safety profile should be reviewed, especially in pediatric use.

> The

> > > development of non-neurotoxic artemisinins is possible and

should

> > be

> > > encouraged.

> > >

> > > Keywords: Artemisinin; Artemether; Artesunate;

> Dihydroartemisinin;

> > > Neurotoxicity; Ototoxicity; Malaria; Cancer

> > >

> > > >

> > > > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

> CMD=search & DB=pubmed

> > > >

> > > > Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

> > > >

> > > > The antimalarial artemisinin synergizes with antibiotics

to

> > > protect

> > > > against lethal live Escherichia coli challenge by decreasing

> > > > proinflammatory cytokine release.

> > > >

> > > > * Wang J, Zhou H, Zheng J, etc.

> > > >

> > > > Department of Pharmacology, College of Medicine, The

Third

> > > Military

> > > > Medical University, Gaotanyan Street 30, Shapingba District,

> > > Chongqing

> > > > 400038, People's Republic of China.

> > > >

> > > > In the present study artemisinin (ART) was found to have

> > potent

> > > > anti-inflammatory effects in animal models of sepsis induced

by

> > > > CpG-containing oligodeoxy-nucleotides (CpG ODN),

> > lipopolysaccharide

> > > > (LPS), heat-killed Escherichia coli 35218 or live E. coli.

> > > Furthermore,

> > > > we found that ART protected mice from a lethal challenge by

CpG

> > > ODN,

> > > > LPS, or heat-killed E. coli in a dose-dependent manner and

that

> > the

> > > > protection was related to a reduction in serum tumor necrosis

> > > factor

> > > > alpha (TNF-alpha). More significantly, the administration of

> ART

> > > > together with ampicillin or unasyn (a complex of ampicillin

and

> > > > sulbactam) decreased mortality from 100 to 66.7% or 33.3%,

> > > respectively,

> > > > in mice subjected to a lethal live E. coli challenge.

Together

> > with

> > > the

> > > > observation that ART alone does not inhibit bacterial growth,

> > this

> > > > result suggests that ART protection is achieved as a result

of

> > its

> > > > anti-inflammatory activity rather than an antimicrobial

effect.

> > In

> > > > RAW264.7 cells, pretreatment with ART potently inhibited TNF-

> > alpha

> > > and

> > > > interleukin-6 release induced by CpG ODN, LPS, or heat-killed

> E.

> > > coli in

> > > > a dose- and time-dependent manner. Experiments utilizing

> affinity

> > > sensor

> > > > technology revealed no direct binding of ART with CpG ODN or

> LPS.

> > > Flow

> > > > cytometry further showed that ART did not alter binding of

CpG

> > ODN

> > > to

> > > > cell surfaces or the internalization of CpG ODN. In addition,

> > > > upregulated levels of TLR9 and TLR4 mRNA were not attenuated

by

> > ART

> > > > treatment. ART treatment did, however, block the NF-kappaB

> > > activation

> > > > induced by CpG ODN, LPS, or heat-killed E. coli. These

findings

> > > provide

> > > > compelling evidence that ART may be an important potential

drug

> > for

> > > > sepsis treatment.

> > > >

> > > > PMID: 16801421 [PubMed - in process]

> > > >

> > >

> >

>

August 11, 2006

Tony,

I no longer take antibiotics at low dose. I am pretty much back to

what used to work for me, plus Recuperation and extra magnesium.

Over 11 years I have been on a lot of different antibiotics. Most did

nothing for me and the quinolones were a disaster. But I understand

what you are saying about others not reacting as I did.

I remember in 1996 being told by Dr. Blanchard from Paris, " Most

mycoplasmas do not respond well to Zithromax, but if it is working

for you keep on. Even bacteria in the same family may not be quite

the same. "

a

>

> a

> You have to be carefull not to hang your hat highly on a drug

that's

> worked well for yourself as a guide to what's good and bad(zithro).

I

> have seen many samples of bacteria that respond wildly, differently

> to many agents and trevoars drug choices leave a lot to be

> desired...especvially the low dose aspect that he stole straight

out

> of brown's arthritic site.I actually see first hand how using a

drug

> like minocycline grows bacteria in the low level presence of the

> drug. I actually saw a great documentary on fake drugs and there

> impact on the nigerian health system..This is a quote fromn the

> female minister, a doctor/pharmacologist explaining that tyhe low

> levels of chloroquine in the fake drugs are worse than anything she

> has encountered, because now all the countries malaria treatments

> see's the parasite use the chloroquine as food to grow.

> I also see aspects of this in the false herxheimer experiment

> practised on unwitting human beings over at the umentionable site-

> with the umentionable latest release DVD's ..not to mention the

> aussie chick from queensland and the meg ryan nursy answering the

> guru's calling.

>

> > > >

> > > > Artemisinin may synergize with your brain cells as well. I

can

> > send

> > > > the full article on this to anyone interested. (You folks are

> so

> > > > adamantly opposed to the MP, you should be as adamantly

opposed

> > to

> > > > artimisinin.)

> > > >

> > > > Toxicology Letters

> > > > Article in Press, Corrected Proof - Note to users

> > > >

> > > > This Document

> > > >

> > > > SummaryPlus

> > > > Full Text + Links

> > > > PDF (200 K)

> > > >

> > > > Actions

> > > >

> > > > Cited By

> > > >

> > > > Save as Citation Alert

> > > >

> > > > E-mail Article

> > > >

> > > > Export Citation

> > > >

> > > > doi:10.1016/j.toxlet.2006.06.001

> > > > Mini review

> > > > Are currently deployed artemisinins neurotoxic?

> > > >

> > > > Tooveya, b, ,

> > > >

> > > > aRoyal Free and University College Medical School, London, UK

> > > > bTravel Clinic, Cape Town, South Africa

> > > >

> > > > Received 28 April 2006; revised 31 May 2006; accepted 1

June

> > > 2006.

> > > > Available online 7 June 2006.

> > > >

> > > > Abstract

> > > > In vitro, animal, and human clinical studies suggest

currently

> > > > deployed artemisinins possess neurotoxic potential. A

specific

> > and

> > > > consistent pattern of brainstem injuries that includes

auditory

> > > > processing centers has been reported from all laboratory

> animals

> > > > studied. Hearing loss, ataxia, and tremor are reported from

> > humans.

> > > > Neurotoxicity appears mediated in part through artemisinin

> > induced

> > > > oxidative stress in exposed brainstems. In vitro studies

> suggest

> > > that

> > > > artemisinin neurotoxicity does not manifest immediately upon

> > > > exposure, but that once commenced it is inevitable and

> > > irreversible;

> > > > extrapolation from in vitro data suggests that 14 days may

> > possibly

> > > > be required for full development, casting doubt upon some

> animal

> > > > safety studies and human necropsy studies. Uncertainty

remains

> > over

> > > > the neurotoxicity of currently deployed artemisinins, and

their

> > > > safety profile should be reviewed, especially in pediatric

use.

> > The

> > > > development of non-neurotoxic artemisinins is possible and

> should

> > > be

> > > > encouraged.

> > > >

> > > > Keywords: Artemisinin; Artemether; Artesunate;

> > Dihydroartemisinin;

> > > > Neurotoxicity; Ototoxicity; Malaria; Cancer

> > > >

> > > > >

> > > > > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

> > CMD=search & DB=pubmed

> > > > >

> > > > > Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

> > > > >

> > > > > The antimalarial artemisinin synergizes with

antibiotics

> to

> > > > protect

> > > > > against lethal live Escherichia coli challenge by

decreasing

> > > > > proinflammatory cytokine release.

> > > > >

> > > > > * Wang J, Zhou H, Zheng J, etc.

> > > > >

> > > > > Department of Pharmacology, College of Medicine, The

> Third

> > > > Military

> > > > > Medical University, Gaotanyan Street 30, Shapingba

District,

> > > > Chongqing

> > > > > 400038, People's Republic of China.

> > > > >

> > > > > In the present study artemisinin (ART) was found to

have

> > > potent

> > > > > anti-inflammatory effects in animal models of sepsis

induced

> by

> > > > > CpG-containing oligodeoxy-nucleotides (CpG ODN),

> > > lipopolysaccharide

> > > > > (LPS), heat-killed Escherichia coli 35218 or live E. coli.

> > > > Furthermore,

> > > > > we found that ART protected mice from a lethal challenge by

> CpG

> > > > ODN,

> > > > > LPS, or heat-killed E. coli in a dose-dependent manner and

> that

> > > the

> > > > > protection was related to a reduction in serum tumor

necrosis

> > > > factor

> > > > > alpha (TNF-alpha). More significantly, the administration

of

> > ART

> > > > > together with ampicillin or unasyn (a complex of ampicillin

> and

> > > > > sulbactam) decreased mortality from 100 to 66.7% or 33.3%,

> > > > respectively,

> > > > > in mice subjected to a lethal live E. coli challenge.

> Together

> > > with

> > > > the

> > > > > observation that ART alone does not inhibit bacterial

growth,

> > > this

> > > > > result suggests that ART protection is achieved as a result

> of

> > > its

> > > > > anti-inflammatory activity rather than an antimicrobial

> effect.

> > > In

> > > > > RAW264.7 cells, pretreatment with ART potently inhibited

TNF-

> > > alpha

> > > > and

> > > > > interleukin-6 release induced by CpG ODN, LPS, or heat-

killed

> > E.

> > > > coli in

> > > > > a dose- and time-dependent manner. Experiments utilizing

> > affinity

> > > > sensor

> > > > > technology revealed no direct binding of ART with CpG ODN

or

> > LPS.

> > > > Flow

> > > > > cytometry further showed that ART did not alter binding of

> CpG

> > > ODN

> > > > to

> > > > > cell surfaces or the internalization of CpG ODN. In

addition,

> > > > > upregulated levels of TLR9 and TLR4 mRNA were not

attenuated

> by

> > > ART

> > > > > treatment. ART treatment did, however, block the NF-kappaB

> > > > activation

> > > > > induced by CpG ODN, LPS, or heat-killed E. coli. These

> findings

> > > > provide

> > > > > compelling evidence that ART may be an important potential

> drug

> > > for

> > > > > sepsis treatment.

> > > > >

> > > > > PMID: 16801421 [PubMed - in process]

> > > > >

> > > >

> > >

> >

>

August 12, 2006

a

It's not really that true what your thinking or have been

told.Penicillin really cuts thru heaps of organisms and keeps cutting

thru heaps more.My fascination for drugs comes from penicillins

success to cut thru pneumonia with things like pseudonomas in the

picture.What didn't surprise me is that penicillin in high dose still

takes out staph epi's and pseudonomas to truly make it last centuries

wonder drug, and a success in treating pneumonia patients.

You also have to learn to let go of the mycoplasma diagnosis because

your not touching it with zithro- which is a newer macrolide that has

no real mycoplasma characteristics. You also have to learn to accept

that your minor pathogens or oppurtunistic pathogens are more likely

to be at the heart of what your treatments are targeting and the fact

that they keep persisting, like erics latest posting, may give you

remnant's of cells that strike a positive in the mycoplasma

testing.Plus PAula your describing yourself as someone that has got

lbs of organisms crippling you, your not really struck down by some

mysterious organisms when your as debilkitated as you describe quite

often.

I look at the salt part of the recup which ends up in your skin,

which is also at the heart of much of this.If your skin weighs 40

lbs, as your largest organ when it's infected a lb plus of

microorganisms may be the order of the day.I actually lick my arm to

see if I have enough salt in my skin.

ka you also describe what has recently occured to you by someone

probing your throat and the follow up infection and

incapacitation.The problem with our infections is that's how they

look 'LIKE NO INFECTION', yet you have all the symptoms opf a middle

ear infection?I'm a bit at a loss often when you adhere to your

philosophies strongly when the actual picture and description of what

your going thru isn't weighing up.Also the majority of cfs ilnesses

that occur in clusters are really respiratory infections, so your

throat/sinus/lung are at the heart of the ilness... as you have

discovered recently with your own experience.

> > > > >

> > > > > Artemisinin may synergize with your brain cells as well. I

> can

> > > send

> > > > > the full article on this to anyone interested. (You folks

are

> > so

> > > > > adamantly opposed to the MP, you should be as adamantly

> opposed

> > > to

> > > > > artimisinin.)

> > > > >

> > > > > Toxicology Letters

> > > > > Article in Press, Corrected Proof - Note to users

> > > > >

> > > > > This Document

> > > > >

> > > > > SummaryPlus

> > > > > Full Text + Links

> > > > > PDF (200 K)

> > > > >

> > > > > Actions

> > > > >

> > > > > Cited By

> > > > >

> > > > > Save as Citation Alert

> > > > >

> > > > > E-mail Article

> > > > >

> > > > > Export Citation

> > > > >

> > > > > doi:10.1016/j.toxlet.2006.06.001

> > > > > Mini review

> > > > > Are currently deployed artemisinins neurotoxic?

> > > > >

> > > > > Tooveya, b, ,

> > > > >

> > > > > aRoyal Free and University College Medical School, London,

UK

> > > > > bTravel Clinic, Cape Town, South Africa

> > > > >

> > > > > Received 28 April 2006; revised 31 May 2006; accepted 1

> June

> > > > 2006.

> > > > > Available online 7 June 2006.

> > > > >

> > > > > Abstract

> > > > > In vitro, animal, and human clinical studies suggest

> currently

> > > > > deployed artemisinins possess neurotoxic potential. A

> specific

> > > and

> > > > > consistent pattern of brainstem injuries that includes

> auditory

> > > > > processing centers has been reported from all laboratory

> > animals

> > > > > studied. Hearing loss, ataxia, and tremor are reported from

> > > humans.

> > > > > Neurotoxicity appears mediated in part through artemisinin

> > > induced

> > > > > oxidative stress in exposed brainstems. In vitro studies

> > suggest

> > > > that

> > > > > artemisinin neurotoxicity does not manifest immediately

upon

> > > > > exposure, but that once commenced it is inevitable and

> > > > irreversible;

> > > > > extrapolation from in vitro data suggests that 14 days may

> > > possibly

> > > > > be required for full development, casting doubt upon some

> > animal

> > > > > safety studies and human necropsy studies. Uncertainty

> remains

> > > over

> > > > > the neurotoxicity of currently deployed artemisinins, and

> their

> > > > > safety profile should be reviewed, especially in pediatric

> use.

> > > The

> > > > > development of non-neurotoxic artemisinins is possible and

> > should

> > > > be

> > > > > encouraged.

> > > > >

> > > > > Keywords: Artemisinin; Artemether; Artesunate;

> > > Dihydroartemisinin;

> > > > > Neurotoxicity; Ototoxicity; Malaria; Cancer

> > > > >

> > > > > >

> > > > > > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

> > > CMD=search & DB=pubmed

> > > > > >

> > > > > > Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

> > > > > >

> > > > > > The antimalarial artemisinin synergizes with

> antibiotics

> > to

> > > > > protect

> > > > > > against lethal live Escherichia coli challenge by

> decreasing

> > > > > > proinflammatory cytokine release.

> > > > > >

> > > > > > * Wang J, Zhou H, Zheng J, etc.

> > > > > >

> > > > > > Department of Pharmacology, College of Medicine, The

> > Third

> > > > > Military

> > > > > > Medical University, Gaotanyan Street 30, Shapingba

> District,

> > > > > Chongqing

> > > > > > 400038, People's Republic of China.

> > > > > >

> > > > > > In the present study artemisinin (ART) was found to

> have

> > > > potent

> > > > > > anti-inflammatory effects in animal models of sepsis

> induced

> > by

> > > > > > CpG-containing oligodeoxy-nucleotides (CpG ODN),

> > > > lipopolysaccharide

> > > > > > (LPS), heat-killed Escherichia coli 35218 or live E.

coli.

> > > > > Furthermore,

> > > > > > we found that ART protected mice from a lethal challenge

by

> > CpG

> > > > > ODN,

> > > > > > LPS, or heat-killed E. coli in a dose-dependent manner

and

> > that

> > > > the

> > > > > > protection was related to a reduction in serum tumor

> necrosis

> > > > > factor

> > > > > > alpha (TNF-alpha). More significantly, the administration

> of

> > > ART

> > > > > > together with ampicillin or unasyn (a complex of

ampicillin

> > and

> > > > > > sulbactam) decreased mortality from 100 to 66.7% or

33.3%,

> > > > > respectively,

> > > > > > in mice subjected to a lethal live E. coli challenge.

> > Together

> > > > with

> > > > > the

> > > > > > observation that ART alone does not inhibit bacterial

> growth,

> > > > this

> > > > > > result suggests that ART protection is achieved as a

result

> > of

> > > > its

> > > > > > anti-inflammatory activity rather than an antimicrobial

> > effect.

> > > > In

> > > > > > RAW264.7 cells, pretreatment with ART potently inhibited

> TNF-

> > > > alpha

> > > > > and

> > > > > > interleukin-6 release induced by CpG ODN, LPS, or heat-

> killed

> > > E.

> > > > > coli in

> > > > > > a dose- and time-dependent manner. Experiments utilizing

> > > affinity

> > > > > sensor

> > > > > > technology revealed no direct binding of ART with CpG ODN

> or

> > > LPS.

> > > > > Flow

> > > > > > cytometry further showed that ART did not alter binding

of

> > CpG

> > > > ODN

> > > > > to

> > > > > > cell surfaces or the internalization of CpG ODN. In

> addition,

> > > > > > upregulated levels of TLR9 and TLR4 mRNA were not

> attenuated

> > by

> > > > ART

> > > > > > treatment. ART treatment did, however, block the NF-

kappaB

> > > > > activation

> > > > > > induced by CpG ODN, LPS, or heat-killed E. coli. These

> > findings

> > > > > provide

> > > > > > compelling evidence that ART may be an important

potential

> > drug

> > > > for

> > > > > > sepsis treatment.

> > > > > >

> > > > > > PMID: 16801421 [PubMed - in process]

> > > > > >

> > > > >

> > > >

> > >

> >

>

August 12, 2006

Hey Tony,

Look for the caps - not yelling - just the simplest way to reply.

>

> a

> It's not really that true what your thinking or have been

> told.Penicillin really cuts thru heaps of organisms and keeps

cutting

> thru heaps more.My fascination for drugs comes from penicillins

> success to cut thru pneumonia with things like pseudonomas in the

> picture.What didn't surprise me is that penicillin in high dose

still

> takes out staph epi's and pseudonomas to truly make it last

centuries

> wonder drug, and a success in treating pneumonia patients.

I BELIEVE YOU.WHEN I FIRST GOT SICK IN 1995 I RESPONDED NICELY TO

PENICILLIN, BUT WAS STILL VERY SICK AFTER MY THROAT HEALED.

> You also have to learn to let go of the mycoplasma diagnosis

because

> your not touching it with zithro- which is a newer macrolide that

has

> no real mycoplasma characteristics.

PLEASE REALIZE THAT IN 11 YEARS I HAVE BEEN ON LONGTERM JUST ABOUT

EVERY ANTIBIOTIC FAMILY THERE IS. I DOUBT THERE IS ANYTHING LEFT FOR

ME TO TRY. I DON'T EVEN KNOW IF I NEED ANY ANTIBIOTICS AT THIS POINT.

You also have to learn to accept

> that your minor pathogens or oppurtunistic pathogens are more

likely

> to be at the heart of what your treatments are targeting and the

fact

> that they keep persisting, like erics latest posting, may give you

> remnant's of cells that strike a positive in the mycoplasma

> testing.Plus PAula your describing yourself as someone that has got

> lbs of organisms crippling you, your not really struck down by some

> mysterious organisms when your as debilkitated as you describe

quite

> often.

HOW OFTEN? I HAVEN'T HAD ANYTHING EXCEPT SEVERE TENDON AND CNS DAMAGE

FROM QUINOLONES IN THREE YEARS. RECENTLY, 3 MONTHS AGO SOMETHING VERY

STRANGE OCCURED UNLIKE ANY SYMPTOMS I HAVE EVER HAD - THE THROAT

INFECTION WHICH CLEARLY WAS CANDIDIASIS COMBINED WITH SOME OTHER

BACTERIA. I TOOK 3 WEEKS OF DIFLUCAN AND WITH A NEGATIVE THROAT

CULTURE I DON'T HAVE ANY DOCTOR WHO WILL TREAT ANYTHING ELSE. I DON'T

KNOW WHAT CAUSED THE NERVE DAMAGE AND VERTIGO, OR IF THE INFECTION IS

STILL THERE. THE SORE THROAT HAS CLEARED.

> I look at the salt part of the recup which ends up in your skin,

> which is also at the heart of much of this.If your skin weighs 40

> lbs, as your largest organ when it's infected a lb plus of

> microorganisms may be the order of the day.I actually lick my arm

to

> see if I have enough salt in my skin.

HAVE YOU READ MARK LONDON'S PAPER ON WHY RECUPERATION MAY WORK? IT

FITS MY SITUATION. HERE IS THE LINK. IF YOU HAVEN'T READ IT I WOULD

BE INTERESTED IN WHAT YOU THINK.

http://web.mit.edu/london/www/RRR.htm

> ka you also describe what has recently occured to you by

someone

> probing your throat and the follow up infection and

> incapacitation.The problem with our infections is that's how they

> look 'LIKE NO INFECTION', yet you have all the symptoms opf a

middle

> ear infection?I'm a bit at a loss often when you adhere to your

> philosophies strongly when the actual picture and description of

what

> your going thru isn't weighing up.Also the majority of cfs ilnesses

> that occur in clusters are really respiratory infections, so your

> throat/sinus/lung are at the heart of the ilness... as you have

> discovered recently with your own experience.

I AM SURE YOU ARE RIGHT, BUT I AM NOT SURE HOW IN THE WORLD TO GET AN

ACCURATE DIAGNOSIS OR ANY TREATMENT.AND MY DOCTOR IS PRETTY OPEN TO

TRYING ANYTHING. SO SHOULD I JUST ASK HER FOR SOME PENICILLIN????

PAULA

>

> > > > > >

> > > > > > Artemisinin may synergize with your brain cells as well.

I

> > can

> > > > send

> > > > > > the full article on this to anyone interested. (You folks

> are

> > > so

> > > > > > adamantly opposed to the MP, you should be as adamantly

> > opposed

> > > > to

> > > > > > artimisinin.)

> > > > > >

> > > > > > Toxicology Letters

> > > > > > Article in Press, Corrected Proof - Note to users

> > > > > >

> > > > > > This Document

> > > > > >

> > > > > > SummaryPlus

> > > > > > Full Text + Links

> > > > > > PDF (200 K)

> > > > > >

> > > > > > Actions

> > > > > >

> > > > > > Cited By

> > > > > >

> > > > > > Save as Citation Alert

> > > > > >

> > > > > > E-mail Article

> > > > > >

> > > > > > Export Citation

> > > > > >

> > > > > > doi:10.1016/j.toxlet.2006.06.001

reserved.

> > > > > > Mini review

> > > > > > Are currently deployed artemisinins neurotoxic?

> > > > > >

> > > > > > Tooveya, b, ,

> > > > > >

> > > > > > aRoyal Free and University College Medical School,

London,

> UK

> > > > > > bTravel Clinic, Cape Town, South Africa

> > > > > >

> > > > > > Received 28 April 2006; revised 31 May 2006; accepted 1

> > June

> > > > > 2006.

> > > > > > Available online 7 June 2006.

> > > > > >

> > > > > > Abstract

> > > > > > In vitro, animal, and human clinical studies suggest

> > currently

> > > > > > deployed artemisinins possess neurotoxic potential. A

> > specific

> > > > and

> > > > > > consistent pattern of brainstem injuries that includes

> > auditory

> > > > > > processing centers has been reported from all laboratory

> > > animals

> > > > > > studied. Hearing loss, ataxia, and tremor are reported

from

> > > > humans.

> > > > > > Neurotoxicity appears mediated in part through

artemisinin

> > > > induced

> > > > > > oxidative stress in exposed brainstems. In vitro studies

> > > suggest

> > > > > that

> > > > > > artemisinin neurotoxicity does not manifest immediately

> upon

> > > > > > exposure, but that once commenced it is inevitable and

> > > > > irreversible;

> > > > > > extrapolation from in vitro data suggests that 14 days

may

> > > > possibly

> > > > > > be required for full development, casting doubt upon some

> > > animal

> > > > > > safety studies and human necropsy studies. Uncertainty

> > remains

> > > > over

> > > > > > the neurotoxicity of currently deployed artemisinins, and

> > their

> > > > > > safety profile should be reviewed, especially in

pediatric

> > use.

> > > > The

> > > > > > development of non-neurotoxic artemisinins is possible

and

> > > should

> > > > > be

> > > > > > encouraged.

> > > > > >

> > > > > > Keywords: Artemisinin; Artemether; Artesunate;

> > > > Dihydroartemisinin;

> > > > > > Neurotoxicity; Ototoxicity; Malaria; Cancer

> > > > > >

> > > > > > >

> > > > > > > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

> > > > CMD=search & DB=pubmed

> > > > > > >

> > > > > > > Antimicrob Agents Chemother. 2006 Jul;50(7):2420-7

> > > > > > >

> > > > > > > The antimalarial artemisinin synergizes with

> > antibiotics

> > > to

> > > > > > protect

> > > > > > > against lethal live Escherichia coli challenge by

> > decreasing

> > > > > > > proinflammatory cytokine release.

> > > > > > >

> > > > > > > * Wang J, Zhou H, Zheng J, etc.

> > > > > > >

> > > > > > > Department of Pharmacology, College of Medicine,

The

> > > Third

> > > > > > Military

> > > > > > > Medical University, Gaotanyan Street 30, Shapingba

> > District,

> > > > > > Chongqing

> > > > > > > 400038, People's Republic of China.

> > > > > > >

> > > > > > > In the present study artemisinin (ART) was found to

> > have

> > > > > potent

> > > > > > > anti-inflammatory effects in animal models of sepsis

> > induced

> > > by

> > > > > > > CpG-containing oligodeoxy-nucleotides (CpG ODN),

> > > > > lipopolysaccharide

> > > > > > > (LPS), heat-killed Escherichia coli 35218 or live E.

> coli.

> > > > > > Furthermore,

> > > > > > > we found that ART protected mice from a lethal

challenge

> by

> > > CpG

> > > > > > ODN,

> > > > > > > LPS, or heat-killed E. coli in a dose-dependent manner

> and

> > > that

> > > > > the

> > > > > > > protection was related to a reduction in serum tumor

> > necrosis

> > > > > > factor

> > > > > > > alpha (TNF-alpha). More significantly, the

administration

> > of

> > > > ART

> > > > > > > together with ampicillin or unasyn (a complex of

> ampicillin

> > > and

> > > > > > > sulbactam) decreased mortality from 100 to 66.7% or

> 33.3%,

> > > > > > respectively,

> > > > > > > in mice subjected to a lethal live E. coli challenge.

> > > Together

> > > > > with

> > > > > > the

> > > > > > > observation that ART alone does not inhibit bacterial

> > growth,

> > > > > this

> > > > > > > result suggests that ART protection is achieved as a

> result

> > > of

> > > > > its

> > > > > > > anti-inflammatory activity rather than an antimicrobial

> > > effect.

> > > > > In

> > > > > > > RAW264.7 cells, pretreatment with ART potently

inhibited

> > TNF-

> > > > > alpha

> > > > > > and

> > > > > > > interleukin-6 release induced by CpG ODN, LPS, or heat-

> > killed

> > > > E.

> > > > > > coli in

> > > > > > > a dose- and time-dependent manner. Experiments

utilizing

> > > > affinity

> > > > > > sensor

> > > > > > > technology revealed no direct binding of ART with CpG

ODN

> > or

> > > > LPS.

> > > > > > Flow

> > > > > > > cytometry further showed that ART did not alter binding

> of

> > > CpG

> > > > > ODN

> > > > > > to

> > > > > > > cell surfaces or the internalization of CpG ODN. In

> > addition,

> > > > > > > upregulated levels of TLR9 and TLR4 mRNA were not

> > attenuated

> > > by

> > > > > ART

> > > > > > > treatment. ART treatment did, however, block the NF-

> kappaB

> > > > > > activation

> > > > > > > induced by CpG ODN, LPS, or heat-killed E. coli. These

> > > findings

> > > > > > provide

> > > > > > > compelling evidence that ART may be an important

> potential

> > > drug

> > > > > for

> > > > > > > sepsis treatment.

> > > > > > >

> > > > > > > PMID: 16801421 [PubMed - in process]

> > > > > > >

> > > > > >

> > > > >

> > > >

> > >

> >

>

August 12, 2006

a

As frustrating as this sounds, you have to revisit what you attempted

to do a month earlier with your throat culture. Your dr. has to make

the pathology lab understand that you have a major infection going on

that is affecting your balance, your not interested in have you, or

have you not got strep pyogenes.You really needed that information

whatever was being observed, you got nadda out of that.Imagine if

your throat culture was heavy growth staph epi and nothing else and

it was ignored?That gives you a tinkering in your antimicrobial

approach.

Also I feel that these ilnesses require understanding of your whole

kaleidoscope of what is wrong and right with you.Often people are

given steroids to allow an area to heal, footballers are thrown into

ice baths to clamp the inflammation they acquire during a game. We

have to understand that the general rigmarol of everyday things tie

oin with our ilnesses.You do cpap which I feel enables your body to

get healing oxygen and a good nights sleep.This shouldn't be ignored,

it ties in with your picture. Having joint problems also ties in with

needing a better understanding.I believe you get a huge rebound of

microrganisms doing quinolones when they are stopped, which impact

people differently. I think having cipro resistance in bugs can

create a whole set of ill people in normal society.

Anyways I feel keep going on the recup, it's like the cement you need

to rebuild a damaged body- it acts like a bridging system to get

things where they are not reaching.As you are learning we need to

have several things going on at once to get us better and better. I

am my old self at this point and wake up differently every day. I

wake up with no inflammation now.

Sign In

Re: The antimalarial artemisinin synergizes with antibiotics

Recommended Posts

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Guest guest

Link to comment

Share on other sites

Join the conversation

Activity